Company intelligence / Profile preview

Fairhaven Pharmaceuticals

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Fairhaven’s R&D program developed small molecule antagonists targeting eosinophil activation for inflammatory diseases. All assets were preclinical at time of Liminal BioSciences acquisition, with investigational therapies showing promise in modulating key drivers of inflammation.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Fairhaven Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fairhaven Pharmaceuticals.

Explore the full profile